Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 9 Nov 2026
Promising but preliminary

Bronchoalveolar lavage fluid cfDNA liquid biopsy-guided neoadjuvant lazertinib in resectable EGFR-mutant non-small cell lung cancer: a prospective phase II study.

We evaluated the feasibility of bronchoalveolar lavage fluid cell-free DNA liquid biopsy (BALiquid) as a preoperative epidermal growth factor receptor (EGFR) genotyping platform and assessed the clinical efficacy of neoadjuvant lazertinib in patients with potentially resectable EGFR-mutant NSCLC. BALiquid-guided neoadjuvant lazertinib demonstrated meaningful antitumor activity, favorable surgical outcomes, and an acceptable safety profile in patients with potentially resectable EGFR-mutant NSCLC. © AME Publishing Company.

We evaluated the feasibility of bronchoalveolar lavage fluid cell-free DNA liquid biopsy (BALiquid) as a preoperative epidermal growth factor receptor (EGFR) genotyping platform and assessed the clinical efficacy of neoadjuvant lazertinib in patients with potentially resectable EGFR-mutant NSCLC. BALiquid-guided neoadjuvant lazertinib demonstrated meaningful antitumor activity, favorable surgical outcomes, and an acceptable safety profile in patients with potentially resectable EGFR-mutant NSCLC. © AME Publishing Company.

What the study was

Study design
Clinical trial (phase)
Population
n=128
Sample size
n=128
Category
Early Detection
Maturity
Validated
Journal
Translational lung cancer research

Why it surfaced

⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Early cancer detection (liquid biopsy, ctDNA, cfDNA); Design: Clinical trial (phase); species: unknown

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.